BusinessPoseida Therapeutics Presents Preclinical Data Demonstrating Multiple Therapeutic Advantages from BCMA-Specific CAR-T Program at American Association for Cancer Research Annual MeetingBy Nasdaq OMXApr 4, 2017, 12:01 PM UTC
BusinessOncoMed Presents Preclinical Data for Anti-TIGIT Program at the American Association for Cancer Research Annual Meeting 2017By Nasdaq OMXApr 3, 2017, 5:00 PM UTC
BusinessPeregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual MeetingBy Nasdaq OMXMar 23, 2017, 11:05 AM UTC
BusinessOncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017By Nasdaq OMXMar 2, 2017, 1:31 PM UTC
BusinessOncoMed Announces Multiple Abstracts Related to Anti-TIGIT Program Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2017By Nasdaq OMXMar 2, 2017, 1:31 PM UTC
BusinessGeron Announces Presentation at American Association for Cancer Research Annual MeetingBy Nasdaq OMXMar 2, 2017, 12:30 PM UTC
BusinessPreclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer (TNBC)By Nasdaq OMXOct 24, 2016, 12:05 PM UTC
BusinessOncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016By Nasdaq OMXApr 20, 2016, 12:30 PM UTC
